MRK vs PHAR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PHAR presents a stark contrast between fundamental value and growth momentum, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits explosive earnings growth (104.2% YoY) and a perfect recent track record of earnings beats, it trades at an extreme premium with a P/E of 433.25 and a Price/Book of 41.46. The massive divergence between the current price ($17.33) and the Graham Number ($0.61) indicates the market is pricing in aggressive future expansion rather than current assets. Despite strong analyst optimism and a 'strong_buy' consensus, the razor-thin profit margin (0.76%) leaves the company vulnerable to operational volatility.
Compare Another Pair
Related Comparisons
MRK vs PHAR: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Pharming Group N.V. (PHAR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.